Key result
Genetic deletion of MLK3 in mice subjected to chronic pressure overload worsened cardiac dysfunction and increased left ventricular chamber size compared with wild-type littermates.
MLK3 prevents adverse cardiac remodeling in response to pressure overload via JNK activation, identifying MLK3-JNK signaling as a novel cardioprotective axis.
Answers are grounded in this paper and cite their sources.
MLK3-JNK signaling emerges as a novel cardioprotective axis in pressure overload; leaves open therapeutic targeting in human heart failure.
Myocardial hypertrophy is an independent risk factor for heart failure (HF), yet the mechanisms underlying pathological cardiomyocyte growth are incompletely understood. The c-Jun NH 2 -terminal kinase (JNK) signaling cascade modulates cardiac hypertrophic remodeling, but the upstream factors regulating myocardial JNK activity remain unclear. In this study, we sought to identify JNK-activating molecules as novel regulators of cardiac remodeling in HF. We investigated mixed lineage kinase-3 (MLK3), a master regulator of upstream JNK-activating kinases, whose role in the remodeling process had not previously been studied. We observed increased MLK3 protein expression in myocardium from patients with nonischemic and hypertrophic cardiomyopathy and in hearts of mice subjected to transverse aortic constriction (TAC). Mice with genetic deletion of MLK3 (MLK3 −/− ) exhibited baseline cardiac hypertrophy with preserved cardiac function. MLK3 −/− mice subjected to chronic left ventricular (LV) pressure overload (TAC, 4 wk) developed worsened cardiac dysfunction and increased LV chamber size compared with MLK3 +/+ littermates ( n = 8). LV mass, pathological markers of hypertrophy ( Nppa, Nppb), and cardiomyocyte size were elevated in MLK3 −/− TAC hearts. Phosphorylation of JNK, but not other MAPK pathways, was selectively impaired in MLK3 −/− TAC hearts. In adult rat cardiomyocytes, pharmacological MLK3 kinase inhibition using URMC-099 blocked JNK phosphorylation induced by neurohormonal agents and oxidants. Sustained URMC-099 exposure induced cardiomyocyte hypertrophy. These data demonstrate that MLK3 prevents adverse cardiac remodeling in the setting of pressure overload. Mechanistically, MLK3 activates JNK, which in turn opposes cardiomyocyte hypertrophy. These results support modulation of MLK3 as a potential therapeutic approach in HF. NEW & NOTEWORTHY Here, we identified a role for mixed lineage kinase-3 (MLK3) as a novel antihypertrophic and antiremodeling molecule in response to cardiac pressure overload. MLK3 regulates phosphorylation of the stress-responsive JNK kinase in response to pressure overload and in cultured cardiomyocytes stimulated with hypertrophic agonists and oxidants. This study reveals MLK3-JNK signaling as a novel cardioprotective signaling axis in the setting of pressure overload.
No takes yet. Share an insight, caveat, or question.
Calamaras et al. (2018) studied Myocardial hypertrophy and heart failure. Genetic deletion of MLK3 (MLK3-/-) and pharmacological inhibition (URMC-099) vs. MLK3+/+ littermates and untreated controls was evaluated on Cardiac dysfunction and left ventricular chamber size. Genetic deletion of MLK3 in mice subjected to chronic pressure overload worsened cardiac dysfunction and increased left ventricular chamber size compared with wild-type littermates.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: